Stuart T. Haines, PharmD, BCPS, BCACP, BC-ADM Professor and Vice Chair for Clinical Services Department of Pharmacy Practice and Science University of Maryland School of Pharmacy Baltimore, MD
Joshua J. Neumiller, PharmD, CDE, FASCP Editor-in-Chief, Diabetes Spectrum Associate Professor Department of Pharmacotherapy College of Pharmacy Washington State University Spokane, WA
1.0 Contact Hour (0.1 CEU)
A CPE-certified online monograph with highlights from the American Society of Consultant Pharmacists workshop.
Many older adults with T2DM are experiencing negative health consequences that could be prevented or improved with optimal evidence-based care. The goal of this monograph is to help consultant and senior care pharmacists achieve greater competency in participating in team-based care and following a chronic care model for older adults with T2DM, promoting appropriate individualized glycemic goals for older adults with T2DM, and helping older adults with T2DM achieve blood glucose targets while balancing the benefits and risks of therapies.
NOTE: This activity was presented on October 30, 2015, in conjunction with ASCP's Annual Meeting and Exhibition. Participants who received credit for attending the live presentation on that date are not eligible to receive credit for this online activity. Program Developer/Facilitator
. Target Audience
This activity is intended for consultant and senior care pharmacists as well as other pharmacists involved or interested in senior care pharmacy and the care of older adults with diabetes.
Upon completion of this educational activity, the participant should be able to:
Outline team-based strategies and emerging new models of care to improve outcomes for older adults with T2DM.
Discuss factors that must be considered when setting glycemic goals for older patients with T2DM.
Outline strategies to overcome common barriers to optimal glycemic control in older adults with T2DM.
Recommend treatment adjustments for older adults with T2DM experiencing hypoglycemia.
Recommend treatment regimens for older adults with T2DM to maximize benefits for cardiovascular comorbidities.
It is the policy of the ASCP to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Haines: Nothing to disclose
Dr. Neumiller discloses the following:
Research Support—AstraZeneca, Johnson & Johnson, Merck, Novo Nordisk
Consultant—Sanofi, Janssen Pharmaceuticals
Speakers' Bureaus—Janssen Pharmaceuticals, Novo Nordisk
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Baird has no relevant financial relationships to disclose.
Mr. Harting, MCM writer/editor, has no relevant financial conflicts to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity Number: 0203-9999-16-002-H01-P, has been assigned 1.0 Contact Hour (0.1 CEU).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit.
Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test.
This activity will take approximately 1 hour to complete. Commercial Support Statements
Supported by educational grants from Takeda, Novo Nordisk, and Merck.
There are no fees for participating in or receiving credit for this online educational activity.
This activity is designed to be completed within the time designated on this page; pharmacists should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online. Be sure to review both written and audio/slide content.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a statement of credit, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, American Society of Consultant Pharmacists, Takeda, Novo Nordisk, or Merck. Any medications, diagnostic procedures, or treatments discussed by the activity presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.